The 2010 winter saw an excess of serious adverse events linked to the CSL influenza vaccine. With another influenza season over, the MJA investigates what progress has been made to ensure it does not happen again.
Eighteen months ago, Dr Darryl Maher received news that changed his working life. He learnt that the seasonal influenza vaccine made by CSL Biotherapies had been linked to serious adverse reactions in children, such as high fevers and febrile seizures.
- 1. Therapeutic Goods Administration. Overview of vaccine regulation and safety monitoring and investigation into adverse events following 2010 seasonal influenza vaccination in young children. Canberra: TGA, 2010.
- 2. Bita N. Virus in the system. The Australian 2011; 28 May.
- 3. WA Department of Health. Ministerial Review into the Public Health Response into the Adverse Events to the Seasonal Influenza Vaccine. First report to the Minister for Health, July 2010 [Stokes report]. Perth: WA Health, 2010.
- 4. Centers for Disease Control and Prevention (US). ACIP recommendation for use of CSL influenza vaccine [media statement]. 6 Aug 2010. http://www.cdc.gov/media/pressrel/2010/s100806.htm (accessed Oct 2011).
- 5. Armstrong PK, Dowse GK, Effler PV, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 2011; 1: e000016. doi:10.1136/bmjopen-2010-000016.
- 6. Department of Health and Ageing. Review of the management of adverse events associated with Panvax and Fluvax. Final report, 10 March 2011 [Horvath report]. Canberra: DoHA, 2011.
- 7. Department of Health and Ageing. Australian Technical Advisory Group on Immunisation (ATAGI) Statement. Clinical advice for immunisation providers regarding the administration of 2011 trivalent seasonal influenza vaccines. March 2011. http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-atagi-vaccine-advice (accessed Oct 2011).
- 8. World Health Organization. Influenza vaccine viruses and reagents. WHO, 2011. http://www.who.int/influenza/vaccines/virus/en/ (accessed Oct 2011).
- 9. Jefferson T, Rivetti A, Harnden A, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008; (2): CD004879.
- 10. ClincalTrials.gov. Safety study of CSL Limited’s influenza virus vaccine in the paediatric population aged ≥ 6 months to < 18 years. http://clinicaltrials.gov/ct2/show/study/NCT00825162?sect=X0125 (accessed Oct 2011).
- 11. ClinicalTrials.gov. A study to determine the immunogenicity and safety profile of CSL Limited’s influenza virus vaccine compared to a US licensed comparator influenza virus vaccine in a pediatric population. http://clinicaltrials.gov/ct2/show/results/NCT00959049 (accessed Aug 2011).
- 12. Nolan T, Richmond PC, McVernon J, et al. Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children. Influenza Other Respi Viruses 2009; 3: 315-325.
- 13. CSL Biotherapies. Fluvax for season 2010. Product information, November 2009. Melbourne: CSL, 2009.
- 14. CSL Biotherapies. Fluvax for season 2011. Product information, October 2010. Melbourne: CSL, 2010.
- 15. Kelly HA, Skowronski DM, De Serres G, Effler PV. Adverse events associated with 2010 CSL and other inactivated influenza vaccines. Med J Aust 2011; 195: 317-319. <MJA full text>
- 16. Food and Drug Administration (US). Inspections, compliance, enforcement, and criminal investigations. Warning letter to Commonwealth Serum Laboratories (CSL) Ltd. June 15, 2011. http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm259888.htm (accessed Oct 2011).
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.